301 related articles for article (PubMed ID: 36980226)
21. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma.
Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA
Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682
[TBL] [Abstract][Full Text] [Related]
22. Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells.
Mise N; Takami M; Suzuki A; Kamata T; Harada K; Hishiki T; Saito T; Terui K; Mitsunaga T; Nakata M; Ikeuchi T; Nakayama T; Yoshida H; Motohashi S
Cancer Sci; 2016 Mar; 107(3):233-41. PubMed ID: 26749374
[TBL] [Abstract][Full Text] [Related]
23. Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy.
Iguchi M; Yagyu S; Kambe K; Higashi M; Fumino S; Kishida T; Iehara T; Mazda O; Tajiri T
Anticancer Res; 2023 Jun; 43(6):2417-2424. PubMed ID: 37247922
[TBL] [Abstract][Full Text] [Related]
24. "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.
Liu KX; Joshi S
Front Immunol; 2020; 11():1947. PubMed ID: 32983125
[TBL] [Abstract][Full Text] [Related]
25. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Mora J
Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
[TBL] [Abstract][Full Text] [Related]
26. Plasticity of NK cells in Cancer.
Corvino D; Kumar A; Bald T
Front Immunol; 2022; 13():888313. PubMed ID: 35619715
[TBL] [Abstract][Full Text] [Related]
27. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
28. The role of macrophage in regulating tumour microenvironment and the strategies for reprogramming tumour-associated macrophages in antitumour therapy.
Xu L; Xie X; Luo Y
Eur J Cell Biol; 2021 Mar; 100(2):151153. PubMed ID: 33476912
[TBL] [Abstract][Full Text] [Related]
29. Metabolic reprograming of tumor-associated macrophages.
Puthenveetil A; Dubey S
Ann Transl Med; 2020 Aug; 8(16):1030. PubMed ID: 32953830
[TBL] [Abstract][Full Text] [Related]
30. Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer.
Imam S; Dar P; Paparodis R; Almotah K; Al-Khudhair A; Hasan SA; Salim N; Jaume JC
J Immunother Cancer; 2019 Jan; 7(1):3. PubMed ID: 30616690
[TBL] [Abstract][Full Text] [Related]
31. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
32. Efficient Killing of High Risk Neuroblastoma Using Natural Killer Cells Activated by Plasmacytoid Dendritic Cells.
Cordeau M; Belounis A; Lelaidier M; Cordeiro P; Sartelet H; Herblot S; Duval M
PLoS One; 2016; 11(10):e0164401. PubMed ID: 27716850
[TBL] [Abstract][Full Text] [Related]
33. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
Front Immunol; 2019; 10():2816. PubMed ID: 31849984
[TBL] [Abstract][Full Text] [Related]
34. Molecular Repolarisation of Tumour-Associated Macrophages.
van Dalen FJ; van Stevendaal MHME; Fennemann FL; Verdoes M; Ilina O
Molecules; 2018 Dec; 24(1):. PubMed ID: 30577495
[TBL] [Abstract][Full Text] [Related]
35. Crosstalk between macrophages and natural killer cells in the tumor microenvironment.
Zhou J; Zhang S; Guo C
Int Immunopharmacol; 2021 Dec; 101(Pt B):108374. PubMed ID: 34824036
[TBL] [Abstract][Full Text] [Related]
36. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.
Esser R; Müller T; Stefes D; Kloess S; Seidel D; Gillies SD; Aperlo-Iffland C; Huston JS; Uherek C; Schönfeld K; Tonn T; Huebener N; Lode HN; Koehl U; Wels WS
J Cell Mol Med; 2012 Mar; 16(3):569-81. PubMed ID: 21595822
[TBL] [Abstract][Full Text] [Related]
37. Macrophage barrier in the tumor microenvironment and potential clinical applications.
Ji S; Shi Y; Yin B
Cell Commun Signal; 2024 Jan; 22(1):74. PubMed ID: 38279145
[TBL] [Abstract][Full Text] [Related]
38. Targeting tumor-associated macrophages for cancer immunotherapy.
Cao X; Lai SWT; Chen S; Wang S; Feng M
Int Rev Cell Mol Biol; 2022; 368():61-108. PubMed ID: 35636930
[TBL] [Abstract][Full Text] [Related]
39. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]